Innovating For Patients

Trevena is a biopharmaceutical company focused on developing and commercializing novel medicines for patients with central nervous system (CNS) disorders.

About Us

Targeted and Innovative CNS Therapies

Trevena’s novel pipeline includes five product candidates that are being developed for areas of critical need in CNS and other disorders.  All of the company’s assets are new chemical entities with unique mechanisms of action that target well-known receptors.  OLINVYK™ is approved by the FDA.  Please see Important Safety Information including Boxed Warning in the full prescribing information available at OLINVYK.com.

Program Molecular Target Therapeutic Target Current Phase PC PH1 PH2 PH3 NDA Now Approved
OLINVYK™ (oliceridine) injection Mu receptor Acute pain Now Approved Intravenous PC complete PH1 complete PH2 complete PH3 complete NDA complete Now Approved in progress
TRV027 AT1 receptor ARDS / abnormal clotting (COVID-19) PH1 Intravenous PC complete PH1 in progress PH2 not started PH3 not started NDA not started Now Approved not started
TRV250 Delta receptor Acute migraine PH1 Oral/Subcutaneous PC complete PH1 in progress PH2 not started PH3 not started NDA not started Now Approved not started
TRV734 Mu receptor Opioid use disorder PH1 Oral PC complete PH1 in progress PH2 not started PH3 not started NDA not started Now Approved not started
TRV045 S1P receptor CNS disorders PC Oral PC in progress PH1 not started PH2 not started PH3 not started NDA not started Now Approved not started
The pipeline assets are investigational products not approved by FDA for sale or distribution in the U.S.

TRV250

Acute treatment of migraine.

About TRV250

TRV734

Maintenance treatment of opioid use disorder.

About TRV734

TRV045

Treatment of various CNS disorders.

About TRV045

TRV027

Treatment of acute lung injury / acute respiratory distress syndrome (ARDS) in COVID-19 patients

About TRV027